Health

Researchers are using firefly genes to understand the biology of cannabis

Doctors at the Sapphire Medical Clinic will present key findings on medical cannabis at an international conference this weekend.

Since 2018, UK doctors have been prescribing medical cannabis for several symptoms, including chronic pain, anxiety, and post-traumatic stress disorders.

With more and more patients being treated today, a significant barrier to access is the lack of adequate evidence to enable the NHS to fund. Medical cannabis.

But thanks to the efforts of doctors and scientists, the UK is now leading the way in medical cannabis research.

Saturday, June 25, Sapphire Medical Clinic Twenty individual studies will be presented at the Annual Conference of the International Cannabinoid Research Association (ICRS) in Galway, Ireland.

In it, they describe the results and safety of medical cannabis therapy in patients with a wide range of disabilities, including but not limited to: Chronic pain, anxiety, Post-traumatic stress disorderInsomnia, and childhood epilepsy.

In this vast study, they present data from Europe’s largest custom medical cannabis registry. UK Medical Cannabis Registry, Currently, more than 5,000 patients are enrolled.

This latest analysis reports outcomes for approximately 2,833 patients with various conditions prescribed for medical cannabis since 2019.

Symptoms included chronic non-cancer pain, anxiety, fibromyalgia, and neuropathic pain. The average age of the patients was 42 years and 43% were female. Patients were evaluated across a variety of validated indicators to assess changes in health at 1, 3, 6, and 12 months.

Researchers report: “This study is the largest observation series of patients prescribed cannabis-based medications in the United Kingdom and shows an association with general health-related quality of life improvements up to 12 months.

In addition, certain improvements in generalized anxiety disorder and sleep quality were observed. The majority of adverse events were mild and moderate. ”

They added: “Randomized controlled trials are essential to determine causality, but this study helps inform current and future trials and is also a fundamental element of pharmacovigilance.”

Apart from pain, researchers have published other studies examining medical cannabis for the treatment of palliative care, headache disorders, insomnia, depression, post-traumatic stress disorders, and inflammatory bowel disease. ..

World-leading research

Regarding the findings, Dr. Simon Eridge, Head of Research and Access at Sapphire Medical Clinic, said: “Medical cannabis is not a panacea and not all patients respond to treatment.

“But from the latest review of the literature published in the British Medical Journal of Medical Cannabis Oil in Chronic Pain, we know that they improve a patient’s pain score by an average of 10 percent. That sounds less. It may not be, but for patients who haven’t helped anything else, this pain relief is of great value. ”

He added: “The studies published at ICRS are a great complement to existing studies and will help us better understand the long-term effects of treatment. Most notably, for health-related quality of life. It demonstrates both condition-specific and overall improvement. These results are reported by patients and directly reflect the changes they experience in their daily lives. ”

The study also showed that, alongside patients unfamiliar with cannabis, patients who had previously had illegal access to cannabis also reported improvements.

Dr. Elridge continues: “Another very interesting finding made through subgroup analysis is that in addition to the group-wide overall improved cannabis-naive patients, similar effect sizes were seen in patients who had previously accessed illegal cannabis. That is .. This suggests that the quality and consistency of medical cannabis prescribed by trained professionals is an important aspect of cannabis-based treatment. ”

He described the UK as the “leader” in medical cannabis research, but emphasized the need for a state agency to fund more randomized controlled trials, along with real-world evidence.

He added: “We are pleased to play a role in ensuring that the UK is a leader in medical cannabis research through the collection, analysis and publication of this data, but randomized controlled trials are still needed.

“In order for the UK to stay at the forefront, funding organizations such as the National Institutes of Health will provide promising signals for our research, as well as funding for randomized controlled trials. It is important to be aware of the potential implications. ”

“In the meantime, we will continue to publicize the promising real-world impacts of British patients.”

House »» Chemistry »» Researchers are using firefly genes to understand the biology of cannabis

Researchers are using firefly genes to understand the biology of cannabis

Source link Researchers are using firefly genes to understand the biology of cannabis

Related Articles

Back to top button